


1642



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

Docket Number:  
11245/46212

Application Number  
**10/090,711**

Filing Date  
**March 4, 2002**

Examiner

Art Unit  
**1642**

Invention Title  
**MONOCLONAL ANTIBODIES SPECIFIC TO VEGF  
RECEPTORS AND USES THEREOF**


Inventor(s)  
**ROCKWELL et al.**

Address to:

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the  
United States Postal Service with sufficient postage as first class mail in an envelope  
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-  
1450 on

Date: February 6, 2004


By:   
Kathryn M. Lumb (Reg. No. 46,885)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: February 6, 2004

By:   
Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (Telephone)  
(212) 425-5288 (Facsimile)  
**CUSTOMER NO. 26646**



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

Docket Number:  
**11245/46212**

Application Number  
**10/090,711**

Filing Date  
**March 4, 2002**

Examiner

Art Unit  
**1642**

Invention Title  
**MONOCLONAL ANTIBODIES SPECIFIC TO VEGF  
RECEPTORS AND USES THEREOF**


Inventor(s)  
**ROCKWELL et al.**

**Address to:**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the  
United States Postal Service with sufficient postage as first class mail in an envelope  
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-  
1450 on


Date: February 6, 2004

By:   
Kathryn M. Lumb (Reg. No. 46,885)


1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
3. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge or credit any over payment to Deposit Account No. 11-0600. A duplicate copy of this communication is enclosed for charging purposes.

Dated: February 6, 2004

By:

  
Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (Telephone)  
(212) 425-5288 (Facsimile)  
CUSTOMER NO. 26646



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>	<b>ATTY. DOCKET NO.</b> 11245/46212	<b>SERIAL NO.</b> 10/090,711
	<b>APPLICANT</b> ROCKWELL, et al.	
	<b>FILING DATE</b> March 4, 2002	<b>GROUP</b> 1642

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	6,342,219	January 29, 2002	Thorpe et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS**

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Johnson D.L. et al., Dual inhibitors of the BFGF and VEGF receptor tyrosine kinases effectively inhibit angiogenesis. Proceedings of the American Associate for Cancer Research March 2000. Vol 41, Page 567. Abstract 3614
	No	Hooper H.A. et al., Vascular endothelial growth factor receptor (VEGFR-2) antibody therapy combined with conventional chemotherapy inhibits growth of established tumors in mice. Proceedings of the American associate for Cancer Research. March 2000 Vol. 41 page 567. Abstract 3613
		Mordenti J. et al., Efficacy and Concentration-response to murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicologic Pathology 1999. Vol. 27, No. 1 pp. 14-21
		Hirota N. et al. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and monoclonal anti-epidermal growth factor receptor antibody. Cancer Research 1989, Vol. 49

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	